Clinical features of MIS-C and COVID-19 in children

  • Funded by Netherlands Organisation for Health Research and Development (ZonMW)
  • Total publications:0 publications

Grant number: 1.04301E+13

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2022
    2024
  • Funder

    Netherlands Organisation for Health Research and Development (ZonMW)
  • Principal Investigator

    EP. Buddingh
  • Research Location

    Netherlands
  • Lead Research Institution

    Leids Universitair Medisch Centrum
  • Research Priority Alignment

    N/A
  • Research Category

    Clinical characterisation and management

  • Research Subcategory

    Disease pathogenesis

  • Special Interest Tags

    Data Management and Data Sharing

  • Study Type

    Clinical

  • Clinical Trial Details

    Not applicable

  • Broad Policy Alignment

    Pending

  • Age Group

    Children (1 year to 12 years)

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

Infection with SARS-CoV-2 can rarely lead to serious illness in children. Children with underlying conditions in particular can sometimes become seriously ill with COVID-19. In addition, you can (mostly previously healthy) children get MIS-C three to six weeks after experiencing a corona infection. MIS-C, or 'multi-system inflammatory disease in children', is a severe inflammatory response throughout the body. This happens to approximately 1 in 5,000 children who get a corona infection. It is a serious disease, for which about half of children end up in intensive care. In the Children have also died abroad. Since the start of the pandemic, pediatricians from more than 35 hospitals in the Netherlands have jointly registered data on children with MIS-C or severe COVID-19. They do this in the context of the COPP study: "Clinical features of COVID-19 in Pediatric Patients". The data entered is automatically analyzed daily and published on the website www.covidkids.nl shown. The information from the COPP study has proven to be very important for advice on vaccinating young children and teenagers in the Netherlands. It will remain essential in the near future to have good information about how sick children after infection with SARS-CoV-2. This is important because of the arrival of new variants, such as omikron. But also to keep track of the effect of vaccination on children occurrence of MIS-C. MIS-C cases are not kept by the GGD or the NICE registration of the hospitals. The aim of the COPP study is to expand the registration to all hospitals in the Netherlands. A complete, timely registration of children with COVID-19 or MIS-C in Dutch hospitals with 'real-time' reporting on the website is important to have continuous insight into the progress of corona infections in children in the Netherlands. We are also investigating the long-term effects of severe COVID-19 or MIS-C in children in the Netherlands.